Swedish Orphan Biovitrum AB (publ)
OTC: BIOVF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Guido Oelkers
- Employees
- 1,895
- Headquarters
- Solna, Sweden
- IPO year
- 2021
- Market cap
- $16.6B
- Website
- https://www.sobi.com
Loading BIOVF…
Loading profile data…Frequently asked questions about BIOVF
What does Swedish Orphan Biovitrum AB (publ) (BIOVF) do?
Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic focus areas encompass hematology, immunology, and a range of genetic and metabolic disorders, with a commercia...
Where does BIOVF trade?
Swedish Orphan Biovitrum AB (publ) (BIOVF) trades on the Other OTC.
What sector is BIOVF in?
Swedish Orphan Biovitrum AB (publ) (BIOVF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Swedish Orphan Biovitrum AB (publ)?
Guido Oelkers is the chief executive officer of Swedish Orphan Biovitrum AB (publ) (BIOVF).
Where is Swedish Orphan Biovitrum AB (publ) headquartered?
Swedish Orphan Biovitrum AB (publ) is headquartered in Sweden.
Does BIOVF pay a dividend?
Swedish Orphan Biovitrum AB (publ) (BIOVF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BIOVF go public?
Swedish Orphan Biovitrum AB (publ) (BIOVF) completed its initial public offering in 2021.